Shire Settles Patent Infringement Lawsuit Against Teva Concerning INTUNIV®

Philadelphia (ots/PRNewswire) -

Shire LLC has settled its litigation against Teva Pharmaceuticals
USA Inc. ("Teva") in connection with Teva's Abbreviated New Drug
Application ("ANDA") for a generic version of Shire's INTUNIV
(guanfacince) Extended Release Tablets for the treatment of Attention
Deficit Hyperactivity Disorder.

The settlement provides Teva with a license to market in the
United States either its own generic versions of INTUNIV or
authorized generic versions of INTUNIV supplied by Shire. The license
takes effect after the expiration of the 180 day exclusivity period
granted to Actavis, as the first ANDA filer. Actavis is licensed by
Shire to market generic product beginning on December 1, 2014.

The litigation involves a patent infringement lawsuit relating to
U.S. patents 6,287,599 ("the '599 Patent"), and 6,811,794 ("the '794
Patent"). A bench trial against Actavis and Teva was held in
September 2012. As Shire has previously settled with Actavis, and has
now settled with Teva, the court will not be issuing a decision on
the trial. As part of the settlement, Teva has confirmed that its
proposed generic products infringe Shire's '599 and '794 Patents and
that the two patents are valid and enforceable with respect to those
proposed generic products.

The agreements, which are effective immediately, have been
submitted to the US Federal Trade Commission for its review as
required by law.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better
lives.

Our strategy is to focus on developing and marketing innovative
specialty medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases,
Gastrointestinal, Internal Medicine and Regenerative Medicine and we
are developing treatments for symptomatic conditions treated by
specialist physicians in other targeted therapeutic areas.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical
facts are forward-looking statements. Forward-looking statements
involve a number of risks and uncertainties and are subject to change
at any time. In the event such risks or uncertainties materialize,
Shire's results could be materially adversely affected. The risks and
uncertainties include, but are not limited to, that:

- Shire's products may not be a commercial success;
- revenues from ADDERALL XR are subject to generic erosion;
- the failure to obtain and maintain reimbursement, or an adequate level of
reimbursement, by third-party payors in a timely manner for Shire's products may
impact future revenues and earnings;
- Shire relies on a single source for manufacture of certain of its products and
a disruption to the supply chain for those products may result in Shire being unable
to continue marketing or developing a product or may result in Shire being unable to
do so on a commercially viable basis;
- Shire uses third party manufacturers to manufacture many of its products and
is reliant upon third party contractors for certain goods and services, and any
inability of these third party manufacturers to manufacture products, or any failure
of these third party contractors to provide these goods and services, in each case in
accordance with its respective contractual obligations, could adversely affect Shire's
ability to manage its manufacturing processes or to operate its business;
- the development, approval and manufacturing of Shire's products is subject to
extensive oversight by various regulatory agencies and regulatory approvals or
interventions associated with changes to manufacturing sites, ingredients or
manufacturing processes could lead to significant delays, increase in operating costs,
lost product sales, an interruption of research activities or the delay of new product
launches;
- the actions of certain customers could affect Shire 's ability to sell or
market products profitably and fluctuations in buying or distribution patterns by such
customers could adversely impact Shire's revenues, financial conditions or results of
operations;
- investigations or enforcement action by regulatory authorities or law
enforcement agencies relating to Shire's activities in the highly regulated markets in
which it operates may result in the distraction of senior management, significant
legal costs and the payment of substantial compensation or fines;
- adverse outcomes in legal matters and other disputes, including Shire's
ability to obtain, maintain, enforce and defend patents and other intellectual
property rights required for its business, could have a material adverse effect on
Shire's revenues, financial condition or results of operations;

and other risks and uncertainties detailed from time to time in
Shire's filings with the U.S. Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K.

For further information please contact:

Investor Relations

Eric Rojas
erojas@shire.com
+1-781-482-0999

Sarah Elton-Farr
seltonfarr@shire.com
+44-1256-894157

Media

Jessica Mann
jmann@shire.com
+44-1256-894-280

Gwen Fisher
gfisher@shire.com
+1-484-595-9836

ots Originaltext: Shire Pharmaceuticals Group Plc
Im Internet recherchierbar: http://www.presseportal.de